Advanced

A new approach to disease-modifying drug trials in Parkinson's disease

Barker, Roger A. ; Stacy, Mark and Brundin, Patrik LU (2013) In Journal of Clinical Investigation 123(6). p.2364-2365
Abstract
Translating new findings in the laboratory into therapies for patients is a slow and expensive process. The development of therapies for neurodegenerative diseases is further complicated by the difficulty in determining whether the drug truly retards the slow degenerative process or provides only symptomatic benefit. In this issue, Aviles-Olmos et al. describe a first in Parkinson's disease (PD) patient study using a drug previously approved for diabetes treatment. In addition to suggesting that the drug may indeed be disease modifying in PD, their innovative approach suggests there may be more rapid and inexpensive avenues for testing novel therapies in PD.
Please use this url to cite or link to this publication:
author
; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Clinical Investigation
volume
123
issue
6
pages
2364 - 2365
publisher
Am Soc Clin Investig
external identifiers
  • wos:000320093100011
  • scopus:84878566284
  • pmid:23728166
ISSN
0021-9738
DOI
10.1172/JCI69690
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Neuronal Survival (013212041)
id
f8bf47ff-2810-41d1-a038-903d2cd85891 (old id 3990336)
date added to LUP
2016-04-01 14:10:40
date last changed
2020-08-19 04:58:45
@misc{f8bf47ff-2810-41d1-a038-903d2cd85891,
  abstract     = {Translating new findings in the laboratory into therapies for patients is a slow and expensive process. The development of therapies for neurodegenerative diseases is further complicated by the difficulty in determining whether the drug truly retards the slow degenerative process or provides only symptomatic benefit. In this issue, Aviles-Olmos et al. describe a first in Parkinson's disease (PD) patient study using a drug previously approved for diabetes treatment. In addition to suggesting that the drug may indeed be disease modifying in PD, their innovative approach suggests there may be more rapid and inexpensive avenues for testing novel therapies in PD.},
  author       = {Barker, Roger A. and Stacy, Mark and Brundin, Patrik},
  issn         = {0021-9738},
  language     = {eng},
  number       = {6},
  pages        = {2364--2365},
  publisher    = {Am Soc Clin Investig},
  series       = {Journal of Clinical Investigation},
  title        = {A new approach to disease-modifying drug trials in Parkinson's disease},
  url          = {https://lup.lub.lu.se/search/ws/files/3828240/4173640.pdf},
  doi          = {10.1172/JCI69690},
  volume       = {123},
  year         = {2013},
}